Cargando…

Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy

Myotonic dystrophy type 1 (DM1) is a dominantly inherited, multisystemic disorder characterized clinically by delayed muscle relaxation and weakness. The disease is caused by a CTG repeat expansion in the 3′ untranslated region (3′ UTR) of the DMPK gene, which leads to the expression of a toxic gain...

Descripción completa

Detalles Bibliográficos
Autores principales: Christou, Melina, Wengel, Jesper, Sokratous, Kleitos, Kyriacou, Kyriacos, Nikolaou, Georgios, Phylactou, Leonidas A., Mastroyiannopoulos, Nikolaos P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133450/
https://www.ncbi.nlm.nih.gov/pubmed/31873063
http://dx.doi.org/10.1089/nat.2019.0811
_version_ 1783517633310621696
author Christou, Melina
Wengel, Jesper
Sokratous, Kleitos
Kyriacou, Kyriacos
Nikolaou, Georgios
Phylactou, Leonidas A.
Mastroyiannopoulos, Nikolaos P.
author_facet Christou, Melina
Wengel, Jesper
Sokratous, Kleitos
Kyriacou, Kyriacos
Nikolaou, Georgios
Phylactou, Leonidas A.
Mastroyiannopoulos, Nikolaos P.
author_sort Christou, Melina
collection PubMed
description Myotonic dystrophy type 1 (DM1) is a dominantly inherited, multisystemic disorder characterized clinically by delayed muscle relaxation and weakness. The disease is caused by a CTG repeat expansion in the 3′ untranslated region (3′ UTR) of the DMPK gene, which leads to the expression of a toxic gain-of-function mRNA. The expanded CUG repeat mRNA sequesters the MBNL1 splicing regulator in nuclear-retained foci structures, resulting in loss of protein function and disruption of alternative splicing homeostasis. In this study, we used CAG repeat antisense oligonucleotides (ASOs), composed of locked nucleic acid (LNA)- and 2′-O-methyl (2′OMe)-modified bases in a chimeric design, to alleviate CUG(expanded)-mediated toxicity. Chimeric 14–18mer LNA/2′OMe oligonucleotides, exhibiting an LNA incorporation of ∼33%, significantly ameliorated the misregulated alternative splicing of Mbnl1-dependent exons in primary DM1 mouse myoblasts and tibialis anterior muscles of DM1 mice. Subcutaneous delivery of 14mer and 18mer LNA/2′OMe chimeras in DM1 mice resulted in high levels of accumulation in all tested skeletal muscles, as well as in the diaphragm and heart tissue. Despite the efficient delivery, chimeric LNA/2′OMe oligonucleotides were not able, even at a high-dosage regimen (400 mg/kg/week), to correct the misregulated splicing of Serca1 exon 22 in skeletal muscles. Nevertheless, oligonucleotide doses were well-tolerated as determined by histological and plasma biochemistry analyses. Our results provide proof of concept that inhibition of MBNL1 sequestration by systemic delivery of a steric-blocking ASO is extremely challenging, considering the large number of target sites that need to be occupied per RNA molecule. Although not suitable for DM1 therapy, chimeric LNA/2′OMe oligonucleotides could prove to be highly beneficial for other diseases, such as Duchenne muscular dystrophy, that require inhibition of a single target site per RNA molecule.
format Online
Article
Text
id pubmed-7133450
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-71334502020-04-06 Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy Christou, Melina Wengel, Jesper Sokratous, Kleitos Kyriacou, Kyriacos Nikolaou, Georgios Phylactou, Leonidas A. Mastroyiannopoulos, Nikolaos P. Nucleic Acid Ther Original Research Reports Myotonic dystrophy type 1 (DM1) is a dominantly inherited, multisystemic disorder characterized clinically by delayed muscle relaxation and weakness. The disease is caused by a CTG repeat expansion in the 3′ untranslated region (3′ UTR) of the DMPK gene, which leads to the expression of a toxic gain-of-function mRNA. The expanded CUG repeat mRNA sequesters the MBNL1 splicing regulator in nuclear-retained foci structures, resulting in loss of protein function and disruption of alternative splicing homeostasis. In this study, we used CAG repeat antisense oligonucleotides (ASOs), composed of locked nucleic acid (LNA)- and 2′-O-methyl (2′OMe)-modified bases in a chimeric design, to alleviate CUG(expanded)-mediated toxicity. Chimeric 14–18mer LNA/2′OMe oligonucleotides, exhibiting an LNA incorporation of ∼33%, significantly ameliorated the misregulated alternative splicing of Mbnl1-dependent exons in primary DM1 mouse myoblasts and tibialis anterior muscles of DM1 mice. Subcutaneous delivery of 14mer and 18mer LNA/2′OMe chimeras in DM1 mice resulted in high levels of accumulation in all tested skeletal muscles, as well as in the diaphragm and heart tissue. Despite the efficient delivery, chimeric LNA/2′OMe oligonucleotides were not able, even at a high-dosage regimen (400 mg/kg/week), to correct the misregulated splicing of Serca1 exon 22 in skeletal muscles. Nevertheless, oligonucleotide doses were well-tolerated as determined by histological and plasma biochemistry analyses. Our results provide proof of concept that inhibition of MBNL1 sequestration by systemic delivery of a steric-blocking ASO is extremely challenging, considering the large number of target sites that need to be occupied per RNA molecule. Although not suitable for DM1 therapy, chimeric LNA/2′OMe oligonucleotides could prove to be highly beneficial for other diseases, such as Duchenne muscular dystrophy, that require inhibition of a single target site per RNA molecule. Mary Ann Liebert, Inc., publishers 2020-04-01 2020-03-26 /pmc/articles/PMC7133450/ /pubmed/31873063 http://dx.doi.org/10.1089/nat.2019.0811 Text en © Melina Christou et al. 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
spellingShingle Original Research Reports
Christou, Melina
Wengel, Jesper
Sokratous, Kleitos
Kyriacou, Kyriacos
Nikolaou, Georgios
Phylactou, Leonidas A.
Mastroyiannopoulos, Nikolaos P.
Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
title Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
title_full Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
title_fullStr Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
title_full_unstemmed Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
title_short Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
title_sort systemic evaluation of chimeric lna/2′-o-methyl steric blockers for myotonic dystrophy type 1 therapy
topic Original Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133450/
https://www.ncbi.nlm.nih.gov/pubmed/31873063
http://dx.doi.org/10.1089/nat.2019.0811
work_keys_str_mv AT christoumelina systemicevaluationofchimericlna2omethylstericblockersformyotonicdystrophytype1therapy
AT wengeljesper systemicevaluationofchimericlna2omethylstericblockersformyotonicdystrophytype1therapy
AT sokratouskleitos systemicevaluationofchimericlna2omethylstericblockersformyotonicdystrophytype1therapy
AT kyriacoukyriacos systemicevaluationofchimericlna2omethylstericblockersformyotonicdystrophytype1therapy
AT nikolaougeorgios systemicevaluationofchimericlna2omethylstericblockersformyotonicdystrophytype1therapy
AT phylactouleonidasa systemicevaluationofchimericlna2omethylstericblockersformyotonicdystrophytype1therapy
AT mastroyiannopoulosnikolaosp systemicevaluationofchimericlna2omethylstericblockersformyotonicdystrophytype1therapy